Navigation Links
Molecule serves as a key in some protein interactions
Date:11/4/2011

Research led by St. Jude Children's Research Hospital scientists has identified an unexpected mechanism facilitating some protein interactions that are the workhorses of cells and, in the process, identified a potential new cancer drug development target.

The discovery involves a chemical known as an acetyl group. An estimated 85 percent of human proteins have this chemical added to the amino acid at one end of the protein. The addition comes in a process known as N-terminal acetylation. N-terminal acetylation occurs shortly after proteins are assembled. Although it has long been known that proteins are N-terminally acetylated, until now it was unknown how such acetylation could serve specific functions.

The findings came from scientists studying a system cells use to regulate the fate and function of proteins. The researchers showed that much like a key must fit precisely to work a lock, the acetylated end of one enzyme fits perfectly into a deep pocket on the surface of another protein. The connection helps accelerate the activity of a protein complex that is involved in regulating cell division and that has been linked to cancer. The research appears in the November 4 print edition of the journal Science.

The findings have potential implications for drug discovery and for understanding basic mechanisms governing the interaction of possibly thousands of proteins, said the study's senior author, Brenda Schulman, Ph.D., a member of the St. Jude Department of Structural Biology and a Howard Hughes Medical Institute investigator.

"The work presents a major new concept in protein-protein interactions," she said. "This raises the question of whether similar 'keys' on thousands of different proteins also unlock doors to allow them to function."

The research offers the first view of how N-terminal acetylation mediates protein interactions, bringing proteins together to do the work of cells. "These findings raise the possibility that N-terminal acetylation plays an important role in the function of a large number of proteins in the cell," said first author, Daniel Scott, Ph.D. a scientist in Schulman's laboratory.

The pocket where N-terminally acetylated proteins bind may also be a good target for small molecules designed to block protein interactions that lead to many diseases, including cancers, Schulman said.

Schulman and her colleagues discovered the pivotal role N-terminal acetylation plays while studying interactions between the proteins Ubc12 and Dcn1. Other researchers have identified human Dcn1 as an oncogene that promotes some squamous cell head, neck and lung cancers.

The focus of the current study was the role the enzymes played in regulating activity of another complex, known as cullin-RING. The cullin-RING complex is the command center of a tagging system that cells use to modify a protein's function or to mark a protein for degradation. The cullin-RING targeted proteins include those that control such important biological processes as cell division and the immune response.

Dcn1 is bound to the cullin protein. In previous studies, Schulman and her colleagues showed that in yeast the Ubc12 and Dcn1 interaction led Ubc12 to transfer its cargo, a protein called NEDD8, to cullin. That step dramatically accelerated the activity of cullin-RING.

But a major question was how human Dcn1 and Ubc12 interact. The breakthrough came when the researchers realized that Ubc12 is among the 35 to 50 percent of proteins in which methionine is the amino acid involved in N-terminal acetylation. The investigators used a variety of laboratory techniques to demonstrate that the acetylated methionine of Ubc12 was essential to the Ubc12-Dcn1 interaction. Evidence included an X-ray image that shows Ubc12's acetyl-methionine buried in a pocket on the surface of Dcn1.

"The size and shape of the pocket indicate it might be a completely new route to generating small- molecule inhibitors," Schulman said. Pharmaceutical companies are already targeting other parts of the same NEDD8 pathway, and one experimental drug has entered clinical trials.

Not only does Ubc12's acetylated tail fit perfectly into the pocket, but acetylation solved another problem that would have made the interaction of Ubc12 and Dcn1 difficult. Without acetylation, Ubc12 and the Dcn1 pocket would repel each other much like oil and water. Acetylation neutralizes the charge on Ubc12, allowing the interaction to occur, Schulman said.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert  

Related biology news :

1. Study identifies molecules used by certain species of seaweed to harm corals
2. Medical College of Wisconsin researchers show molecule inhibits metastasis
3. Sexual selection by sugar molecule helped determine human origins
4. Small molecules can starve cancer cells
5. Small molecule receptor detects lipids telltale sign of cell death
6. New bouncer molecule halts rheumatoid arthritis
7. Small molecules shed light on cancer therapies
8. Regrowing blood vessels with a potent molecule
9. UCLA scientists complete first mapping of molecule found in human embryonic stem cells
10. Molecules light up Alzheimers roots
11. Newly discovered molecule essential to resetting body clocks
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Molecule serves as a key in some protein interactions
(Date:6/2/2016)... , June 2, 2016 ... Manned Platforms, Unmanned Systems, Physical Infrastructure, Support & Other ... provider visiongain offers comprehensive analysis of the ... this market will generate revenues of $17.98 billion in ... acquired DVTEL Inc, a leader in software and hardware ...
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/23/2016)... ... 2016 , ... Mosio, a leader in clinical research patient ... and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the hurdle ... and strategies for clinical researchers. , “The landscape of how patients receive and ...
Breaking Biology Technology: